Kymera Therapeutics (KYMR) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Kymera Therapeutics (KYMR) PT Raised to $41 at B.Riley
November 1, 2024 5:59 AM EDTB.Riley analyst Kalpit Patel raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $41.00 (from $36.00) while maintaining a Neutral rating.
The analyst comments "Kymera Therapeutics (KYMRNeutral, $41 PT) announced 3Q24 earnings and provided a business update. Patient dosing has commenced for KT-621, the companys STAT6 degrader, with... More
